Oncogenes and tumour suppressor genes control the balance between apoptotic death and anti-apoptotic survival signals determining whether a cell proliferates or dies. Through which eectors might oncoproteins generate sensitivity to apoptosis remains to be determined. Ras GTPase activating protein (Ras-GAP) is a key element in the Ras signalling pathway, being both a negative regulator and possibly an eector of Ras. Ras-GAP acts as a regulator of transcription, and possibly connects Ras to stress-activated protein kinases. A role for Ras-GAP in cell survival has been suspected from the study of knock-out mouse embryos. In search for selective killing of tumour cells, we asked whether Ras-GAP inhibition by other means would lead to apoptosis in established cell lines. We injected a monoclonal antibody directed against the SH3 domain of Ras-GAP (mAb200) that has been shown to block Ras-GAP downstream signalling into various human normal and tumour cell lines. We show that inhibition of Ras-GAP induces apoptosis speci®cally in tumour, but not in normal cells, therefore pointing at a speci®c role for Ras-GAP in tumour cell survival. MAb200-induced apoptosis is largely prevented by coinjection of activated RhoA or Cdc42 proteins, by injection of a constitutively activated mutant of phosphoinositide 3-OH kinase (PI3-K), but not by injection of v-Raf. These results show that targeting of Ras-GAP could represent a novel anticancer approach.
Oncogenes and tumour suppressor genes control the balance between apoptotic death and anti-apoptotic survival signals determining whether a cell proliferates or dies. Through which eectors might oncoproteins generate sensitivity to apoptosis remains to be determined. Ras GTPase activating protein (Ras-GAP) is a key element in the Ras signalling pathway, being both a negative regulator and possibly an eector of Ras. Ras-GAP acts as a regulator of transcription, and possibly connects Ras to stress-activated protein kinases. A role for Ras-GAP in cell survival has been suspected from the study of knock-out mouse embryos. In search for selective killing of tumour cells, we asked whether Ras-GAP inhibition by other means would lead to apoptosis in established cell lines. We injected a monoclonal antibody directed against the SH3 domain of Ras-GAP (mAb200) that has been shown to block Ras-GAP downstream signalling into various human normal and tumour cell lines. We show that inhibition of Ras-GAP induces apoptosis speci®cally in tumour, but not in normal cells, therefore pointing at a speci®c role for Ras-GAP in tumour cell survival. MAb200-induced apoptosis is largely prevented by coinjection of activated RhoA or Cdc42 proteins, by injection of a constitutively activated mutant of phosphoinositide 3-OH kinase (PI3-K), but not by injection of v-Raf. These results show that targeting of Ras-GAP could represent a novel anticancer approach.
Keywords: Ras-GAP; apoptosis; RhoA; tumour cells Cancer treatment by chemotherapy and radiotherapy induces apoptosis of both tumour and normal sensitive cells. Cases of resistance to chemotherapy and radiotherapy have been associated with up-regulation of anti-apoptotic pathways and inhibition of apoptotic signals (Arecci, 1995) . The aim of new treatments is to selectively impact on pathways deregulated in tumour cells. Ras proteins (Ha-, Ki-and N-Ras) are involved in many aspects of cell growth, mediating mitogenic and dierentiation signals as well as regulating apoptotic signals, from numerous stimuli to downstream targets. In immortalized cell cultures, activating mutations of the ras genes result in constitutive signalling to downstream elements promoting cell growth, and in the downregulation of apoptotic signals (Fenton et al., 1998) , whereas in untransformed cells, Ras triggers precisely the opposite responses (Kaumann-Zeh et al., 1997; Serrano et al., 1997) . In accordance with this, selective targeting of Ras using a monoclonal antibody was shown to promote apoptosis in various tumour cell lines (Cochet et al., 1998) .
Phenotypic changes associated with ras transformation appear to be mediated by multiple Ras-related small GTP-binding proteins, including Rho and Rac (Qiu, et al., 1995a,b; White et al., 1995) . Key signalling pathways downstream of Ras are the Raf/ERK kinase cascade and PI3-kinase/Akt, both being involved in proliferative and survival signals triggered by Ras (Downward, 1998) . Besides these two well-characterized pathways, a growing body of evidence tends to prove that the p120 Ras GTPase activating protein (Ras-GAP) has eector functions for Ras signalling, some of which are relayed by the SH2/SH3 domains (for review see TocqueÂ et al., 1997) . In particular, Ras-GAP induces gene expression in a Ras-dependent manner (Medema et al., 1992; Schweighoer et al., 1992) and is required for ras-induced transformation (Clark et al., 1997) . Additionally, dierent observations sustain an implication of Ras-GAP in cytoskeleton regulation and cell survival. Ras-GAP knock-out mouse embryos exhibit both vascular defects resulting from altered cell migration, and extensive neuronal cell death (Henkemeyer et al., 1995) . More recently, we have shown that Ras-GAP per se is able to trigger stress ®bre formation by stimulating Rho activity, and that a monoclonal antibody directed against the SH3 domain of Ras-GAP (mAb200 (Mollat et al., 1992) ) speci®cally blocked Rho-dependent cytoskeletal reorganization and DNA synthesis induced by growth factors in mouse Swiss 3T3 ®broblasts (Leblanc et al., 1998) . Thus, Ras-GAP could connect both the Ras and Rho pathways.
In this context, we asked whether Ras-GAP, as an eector of Ras and/or a Rho regulator, was implicated via its SH3 domain in the survival of normal or tumour cells. We report here that microinjection of mAb200 into several tumour cell lines induces massive cell death by apoptosis, which never occurred in normal cells. We also show that RhoA and Cdc42 proteins are able to prevent cell death induced by mAb200. These results underline the implication of additional downstream signalling pathways promoting survival in tumour cells besides the PI3-K/Akt pathway.
Results and discussion

MAb200 speci®cally induces apoptosis of tumour, but not of normal cells
In order to determine whether Ras-GAP, through its SH3 domain, is implicated in normal or tumour cell proliferation and/or survival, the anti-Ras-GAP SH3 antibody mAb200 (SpiBio, Massy, France) was microinjected into various normal and tumour cell lines, and cell behaviour was analysed by time-lapse videomicroscopy for 2 ± 3 days. Cells were maintained at 378C in the presence of 5% CO 2 for the duration of the experiment. Successful microinjection was determined visually at the time of injection. No toxicity nor alteration of the growth rate were observed when mAb200 was injected into normal human dermal ®broblasts (NHDF) and normal human bronchial epithelial (NHBE) cells, as compared to microinjection of an irrelevant IgG (Figure 1 ) or of a monoclonal antibody directed against the carboxyterminal part of Ras-GAP (not shown) under similar conditions. By contrast, when mAb200 was microinjected into lung carcinoma H460 cells, cervix carcinoma HeLa cells and colon carcinoma HCT116 cells, massive cell death occurred ( Figure 1 ). Breast carcinoma SKBR3 cells, non small lung H322 and colon HT29 carcinoma cells were also sensitive to the mAb200 antibody, although to a lesser extent (data not shown). Cells which were not killed were not able to cycle anymore, or at a slower rate. Typically, between 10 and 18 h after injection, about 15% of injected cells die. A peak of cell death was reached about 20 h after injection (40% of H460 or HeLa injected cells died between 18 and 24 h; 30% for HCT116 cells) (Figure 2a and b). After 2 days, about 50% of HCT116 and 70% of H460 and HeLa cells initially injected were killed (Figures 1 and 2c) . As expected, the lethal eect of mAb200 in tumour cells was strongly reduced when the antibody was incubated with puri®ed Ras-GAP protein prior to injection (not shown).
The way tumour cells injected with mAb200 died, that is shrinkage of the cytoplasm and nuclear condensation followed by cell fragmentation is fully consistent with apoptosis. In order to ascertain this hypothesis, the presence of DNA strand breaks, characteristic of apoptotic nuclei, was investigated by TUNEL staining using the In Situ Cell Death Detection kit (Boehringer) at dierent intervals after injection. In agreement with the phenotypic observations, half of injected tumour cells exhibited nuclei with damaged DNA between 12 and 24 h post injection (Figure 3) . No dierence was seen between cells injected with an irrelevant IgG and non-injected cells, background level of apoptosis being less than 5%.
These results indicate that the Ras-GAP pathway regulating growth, through Ras-GAP SH3 domain, is dispensable for normal cell survival, but is essential for some tumour cells to survive since inhibition of Ras-GAP speci®cally induces apoptosis of these cells. The relative importance of the Ras-GAP pathway is probably increased in tumour cells possibly because of the loss of functionality of some survival pathways, or because Ras-GAP has an antiapoptotic function. It is known for instance that the coupling of growth factor receptors to second messengers is largely blunted in cancer cells (Alonso et al., 1990) , and that cancer cells are less sensitive to death signals.
Interestingly, HeLa cells which carry wild-type ras genes, in contrast to H460 and HCT116 cells which carry an activating mutation in the Ki-ras gene, are all eciently killed, suggesting that the cellular status of Figure 1 Eect of mAb200, IgG or Y13-259 injection on the survival of normal and tumour cells. MAb200, mouse IgG or Y13-259 were injected at 10 mg/ml into H460, HCT116, HeLa, NHDF and NHBE cells. Cells were monitored by time-lapse videomicroscopy for 60 h after injection. Injected cells which exhibited the typical features of death were scored. Cell deaths that occurred within the ®rst 6 h post injection were not scored to avoid counting cells that would have undergone physical damage due to the injection itself. The results are given as the percentage of cells which underwent death by apoptosis. All experiments were repeated twice, except (*) which were repeated four times Apoptosis induced by inhibition of Ras-GAP signaling V Leblanc et al ras is not a critical element in mAb200-induced cell death, and that the SH3 domain of Ras-GAP ful®ls an essential function in the survival of transformed cells with both wild-type and mutant ras genes.
These ®ndings are similar to those previously reported with the neutralizing anti-Ras antibody Y13-259 (Cochet et al., 1998) (Figure 1 ). They suggest that apoptosis observed following Ras inhibition in these cell lines may partly result from the lack of activation of the Ras-GAP pathway that is controlled by its SH3 domain. Figure 2 Morphological aspect of mAb200-injected lung carcinoma H460 cells. Phase contrast photographs were taken 7(a), 24(b) and 48 h (c) after microinjection of 10 mg/ml mAb200. Round and refringent cells are cells dead by apoptosis. Black arrows point at some of them. All cells in the ®eld have been injected. Microinjection was performed with an Eppendorf transjector 5246 and an Eppendorf micromanipulator Figure 3 mAb200 injection induces apoptosis in H460 cells. H460 cells were ®xed 15 min in 4% formaldehyde and permeabilized 5 min in 0.2% Triton X-100 16 h after mAb200 injection (10 mg/ml). Injected cells and apoptotic nuclei were detected by¯uorescence using respectively an anti-mouse F(ab') 2 coupled to Texas-Red (a) and by TUNEL staining (b). A phase contrast photography of the corresponding ®eld is shown in (c) Apoptosis induced by inhibition of Ras-GAP signaling V Leblanc et al mAb200-but not Y13-259-induced apoptosis is partially relieved by activated RhoA or Cdc42
We previously showed that Ras-GAP, through its SH3 domain, is able to positively regulate RhoA activity (Leblanc et al., 1998) . We wondered whether RhoA is involved in cell death elicited by neutralization of Ras-GAP SH3 domain. MAb200 was injected into H460 cells along with puri®ed activated RhoA mutant, RhoAV14 (Ridley and Hall, 1992) , and cell behaviour was examined for 2 ± 3 days. About 35% of injected cells underwent apoptosis in the duration of the experiment, that is a twofold reduction in the number of cell deaths compared to that obtained after injection of mAb200 alone (Figure 4) . Importantly, activated RhoA also bypassed the inhibition of cell growth exerted by mAb200: the number of cell divisions scored was tenfold higher in this case. Conversely, when an expression vector encoding RhoAV14 was injected instead of the puri®ed protein, the same protective eect against mAb200-induced apoptosis was observed (not shown). The capacity of the pEXVRhoAV14 plasmid to express a biologically active protein was veri®ed by its ability to induce actin polymerization into stress ®bres after injection into serum-starved Swiss 3T3 ®broblasts as described (Ridley and Hall, 1992) (not shown). A similar protective eect of activated RhoA protein was observed in HCT116 and HeLa cells (data not shown). Since RhoAV14 could prevent the occurring of cell death, it strongly suggested that RhoA sustains at least in part some of the survival signals elicited by Ras-GAP. A role for RhoA in cell survival has already been proposed. Thymocytes where RhoA has been inactivated by a speci®c inhibitor, the exoenzyme C3 of Clostridium botulinum, exhibit a marked increase of apoptosis (Henning et al., 1997) . Moorman and colleagues demonstrated a role for RhoA in murine T lymphoma cell survival (Moorman et al., 1996) . RhoA inactivation led to apoptosis of primary cell explants of chicken embryo ®broblasts and rat aortic smooth muscle cells (Bobak et al., 1997) . Additionally it has recently been shown that Rho activation increases the expression of two antiapoptotic Bcl-2 family members, Bcl-2 and Bcl-x L (Fiorentini et al., 1998) . Finally, the report of Olson and colleagues who showed that RhoA can inhibit the well-known inhibitor of the cell cycle p21
Waf/Cip1 in a context of transformation by ras, could help to understand the role of Rho in tumour cell survival (Olson et al., 1998) .
On the other hand, since activated RhoA is unable to completely rescue cells from dying after Ras-GAP inhibition, it indicates that Ras-GAP SH3 may generate other downstream signals that control cell survival apart from those transmitted to RhoA. These cell survival signals could be for instance directed to the Jun NH2-terminal kinases (Clark et al., 1997) , which are not activated by constitutively active RhoA (Coso et al., 1995) .
It has been proposed that activation of Cdc42 could in turn activate Rac1, which could result in activation of RhoA (Nobes and Hall, 1995) . The ability of a constitutively activated Cdc42 protein, Cdc42V12, to protect cells against mAb200-induced apoptosis was also tested. Cdc42 turned out to be as eective as activated RhoA at blocking cell death (Figure 4) . It is then possible that Cdc42 protective eect results from RhoA activation. This hypothesis is supported by the fact that no additional rescue is seen when RhoA and Cdc42 are coinjected (not shown). Alternatively, since Cdc42 regulates downstream signalling pathways controlling cell growth, such as the JNK/SAPK pathway (Coso et al., 1995; Minden et al., 1995; Teramoto et al., 1996) , it is also p110K227E Figure 4 Eect of Rho proteins and Ras eectors on mAb200-and Y13-259-induced apoptosis in H460 cells. RhoAV14 and Cdc42V12 were puri®ed as described (Ridley and Hall) . HaRasK12 was puri®ed by anion exchange chromatography (Rey et al., 1989) . RhoAV14 (3 mg/ml), Cdc42V12 (3 mg/ml) and Ha-RasK12 (2 mg/ml) proteins were injected into the cytoplasm immediately after injection of IgG, mAb200 or Y13-259 (10 mg/ml). Expression vectors encoding RhoAV14 (0.7 mg/ml), p110K227E (0.7 mg/ ml) and v-Raf (0.5 mg/ml) were injected into cell nuclei 3 h after injection of mAb200 or Y13-259 (10 mg/ml). Cells were monitored by time-lapse videomicroscopy for 60 h after injection and injected cells which exhibited the typical features of apoptosis were scored. The results are given as the percentage of cells which underwent death by apoptosis. All experiments were repeated twice, except (*) which was repeated four times possible that Cdc42 contribute to cell rescue independently of Rho.
The observation that both Ras-GAP and Ras inhibition provoke apoptosis of the same tumour cells, and with a comparable eciency, raised the possibility that these apoptotic events resulted from the inhibition or activation of identical downstream signalling molecules. Therefore, the impact of RhoAV14 and Cdc42V12 on apoptosis caused by Ras inhibition by Y13-259 injection was investigated as well. Strikingly, the rate of cell death was identical in the presence or absence of RhoA or Cdc42 mutants (Figure 4 ). This result indicates that, if small G proteins of the Rho family are involved in cell survival controlled by Ras via Ras-GAP, they are not sucient alone to achieve this eect. By contrast, and as expected, incubation of Ha-RasK12 with Y13-259 prior to injection seriously reduced the ability of the antibody to induce apoptosis (not shown). mAb200-and Y13-259-induced apoptosis are partially relieved by PI3-kinase or v-Raf plus RhoAV14 injection Constitutively activated Ras (Ha-RasK12) was also found to protect cells from apoptosis induced by neutralizing Ras-GAP, indicating that Ras generates some cell survival signals which do not require Ras-GAP (Figure 4 ). To further pinpoint at the role of Ras-GAP in cell survival pathways, we investigated whether the lethality of mAb200 and of Y13-259 was modi®ed upon constitutive activation of PI3 kinase/Akt survival pathway, and whether Raf could cooperate with Rho to prevent cell death. The plasmids encoding an activated mutant of PI3-K, p110K227E (RodriguezViciana et al., 1996) , and an activated form of raf, vRaf (Wasylyk et al., 1988) , were injected into H460 nucleus 3 h after mAb200 or Y13-259 cytoplasmic injection. Ecient plasmid expression was con®rmed by immuno¯uorescence and Western blot analysis (data not shown). P110K227E was very eective at reducing the number of cells dying after mAb200 or Y13-259 microinjection: at least 40% less cells died when activated PI3-kinase was injected with either antibody compared to the eect of the antibodies alone (Figure 4 ). This result suggests that Ras-GAP is not involved downstream of PI3-K to promote cell survival, and con®rms the critical role of PI3-K in cell survival, even in tumour cells.
V-Raf alone was unable to block apoptosis induced by Ras-GAP or Ras inhibition (Figure 4) . In contrast, when cells received both activated RhoA and v-Raf, they became partially resistant to Y13-259-induced apoptosis: 20% of injected cells underwent apoptosis in this case instead of 50 ± 60% observed with Y13-259 injection alone (Figure 4) . These results suggest that at least another survival pathway besides that controlled by PI3-kinase may be involved: signalling cascades downstream of Raf and Rho could collaborate to activate this survival pathway. A co-operation between the Rho and Raf pathways has already been shown in NIH3T3 cells, where Rho potentiates Raf transforming activity (Qiu et al., 1995a or b) . Moreover, a connection between these two pathways has been described in S. cerevisiae where Rho1p, the yeast homologue of RhoA, was shown to regulate yeast MAP kinase and MAP kinase kinase homologues, downstream eectors of Raf (Nonaka et al., 1995) . It is then possible that some elements downstream of Rho A, required for regulating cell survival, need to be activated by signals coming both from Rho, through Ras-GAP, and from Ras, via Raf. Increasing evidence suggests that activation of the Ras-Raf pathway is protective against apoptotic cell death. Raf1 is targeted by Bcl2 to the outer mitochondrial membrane where it phosphorylates Bad (Wang et al., 1996) , Bad phosphorylation impedes the caspase cascade activation, a major pathway leading to cell apoptosis (Salvesen and Dixit, 1996) .
Although more work is needed to understand how the anti-Ras-GAP antibody elicits apoptosis in various tumourigenic cell lines, the present results suggest a selective way of impairing tumour growth by inhibiting Ras-GAP. The tumourigenic cells tested in these experiments do not undergo apoptosis after serum withdrawal and continue to proliferate. One explanation to the selective killing of tumour cells by mAb200 would be that Ras-GAP exerts a negative control on caspase activation, or sustains transcriptional activation of Bcl2 family members, possibly via Rho regulation. Selective inhibition of these pathways would allow the recoupling of cell cycle progression and apoptosis.
